The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Oncolytics Biotech

  • ONC
  • TSX
  • Consumer Products
  • Latest 1.79
  • Currency C$
  • Change 0.14
  • Percent Change 8.485 %
  • Volume 121,903
  • Wed Jul 9, 2014 04:00 PM EDT TSX data delayed 15 minutes.
  • Open 1.66
  • Previous Close 1.65
  • High 1.79
  • Low 1.66
  • Bidx0 1.78
  • Askx0 1.80
  • 52-week High09/09 3.62
  • 52-week Low05/09 1.30
  • Beta 1.032
  • Market Cap 153.60M
  • EPS -0.26
  • P/E
  • Forward P/E
  • PEG
  • Annual Dividend 0.0000
  • Yield
Globe Investor - GIT Upsells
It's never been a better time to get Globe Unlimited
Try Globe Unlimited, featuring new Globe Investor Tools,
for a special trial rate. Only 99¢ for your first month.


Are you a Globe Investor Gold subscriber?
You qualify for complimentary access to Globe Unlimited.
Visit: globeandmail.com/globeplusunlimited
Try it today

News

Financials & Calendars

Income Statement

  • Sales $737,287
  • Earnings $-22,411,262
  • Return on Equity n/a

Cash Flow

  • Cash Flow $-21,414,436
  • Cash $20,155,907
  • Current Ratio 4.66

12 months ended Mar 31, 2014.

Trailing 12 month results shown above.
All data is in Canadian dollars.

Balance Sheet

  • Assets $23,035,683
  • Liabilities $4,833,423
  • Liabilities-to-Equity Ratio 0.27

Price Ratios

  • Price to Sales 206.72
  • Price to Book 8.52
  • Price to Cash Flow -7.12

Event Calendar

Event Last   Next  
Earnings May 8 $-0.07 Aug 7 $-0.07
Surprises May 8 -14.29% n/a n/a
Dividends n/a n/a n/a n/a
Splits n/a -- n/a n/a

12 months ended Jul 10, 2014.

A look at major corporate events and financial announcements that are coming up.

Company Information

About the Company

ONCOLYTICS BIOTECH INC. is a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus.

Related Securities
Symbol Type Latest % Chg

Officers

  • Bradley G. Thompson President & C.E.O. & Chairman
  • Douglas A. Ball C.F.O.
  • Company Type: PUBLIC
  • Company Status: Active
  • Full-time Employees: n/a
  • Incorporation: Canada,
    Apr 2, 1998
  • Top 1000 Ranking: Profit: 0
    Revenue: 0
    Assets: 0

Head Office

Suite 210
Calgary, AB
T2N 1X7

Phone: (403)-670-7377
Fax: (403)-2830858

info@oncolyticsbiotech.com
www.oncolyticsbiotech.com

Ideas & Discussion

Live Discussion of ONC on StockTwits